Literature DB >> 10477086

Intracisternal sauvagine is more potent than corticotropin-releasing factor to decrease gastric vagal efferent activity in rats.

H P Kosoyan1, J Y Wei, Y Taché.   

Abstract

Consecutive intracisternal (ic) injections of corticotropin-releasing factor (CRF) (21, 63, and 126 pmol, ic) or sauvagine (2.1, 6.3, and 21 pmol, ic) decreased gastric vagal efferent multiunit discharge (GVED) to 82%, 75% and 69% and 71%, 40% and 21%, respectively, from preinjection basal levels (taken as 100%). The inhibitory action was dose related (magnitude and duration of the response, 7-45 min). The CRF antagonist, [D-Phe12,Nle21,38,Calpha-MeLeu37]-rCRF12-4 1 (6.25 nmol, ic) increased GVED by 43.5+/-4.3% and blocked the decrease in GVED induced by CRF (21 pmol, ic) for >90 min with a complete recovery after 3 h. Vehicles (injected intracisternally) had no effect. These data indicate that: 1) CRF injected intracisternally decreases GVED through the activation of CRF receptors and sauvagine is more potent than CRF to inhibit GVED; and 2) endogenous CRF exerts an inhibitory tone on basal GVED in urethane-anesthetized rats undergoing surgery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477086     DOI: 10.1016/s0196-9781(99)00072-8

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Central administration of pan-somatostatin agonist ODT8-SST prevents abdominal surgery-induced inhibition of circulating ghrelin, food intake and gastric emptying in rats.

Authors:  A Stengel; M Goebel-Stengel; L Wang; A Luckey; E Hu; J Rivier; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2011-05-13       Impact factor: 3.598

Review 2.  Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.

Authors:  Yvette Tache; Muriel Larauche; Pu-Qing Yuan; Mulugeta Million
Journal:  Curr Mol Pharmacol       Date:  2018       Impact factor: 3.339

3.  Brain-gut interactions between central vagal activation and abdominal surgery to influence gastric myenteric ganglia Fos expression in rats.

Authors:  Marcel Miampamba; Mulugeta Million; Yvette Taché
Journal:  Peptides       Date:  2011-03-02       Impact factor: 3.750

4.  Peripheral corticotropin-releasing factor receptor type 2 activation increases colonic blood flow through nitric oxide pathway in rats.

Authors:  Yasutada Akiba; Jonathan D Kaunitz; Mulugeta Million
Journal:  Dig Dis Sci       Date:  2015-02-21       Impact factor: 3.199

5.  Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2).

Authors:  C-Y Chen; M Million; D W Adelson; V Martínez; J Rivier; Y Taché
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

6.  Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats.

Authors:  Susan K Wood; Robert E Verhoeven; Aaron Z Savit; Kenner C Rice; Peter S Fischbach; James H Woods
Journal:  Neuropsychopharmacology       Date:  2006-05-03       Impact factor: 7.853

7.  In vitro and in vivo analysis of the effects of corticotropin releasing factor on rat dorsal vagal complex.

Authors:  Mark W Lewis; Gerlinda E Hermann; Richard C Rogers; R Alberto Travagli
Journal:  J Physiol       Date:  2002-08-15       Impact factor: 5.182

8.  Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  J Neurogastroenterol Motil       Date:  2011-07-13       Impact factor: 4.924

9.  Auricular Vagus Nerve Stimulation Ameliorates Functional Dyspepsia with Depressive-Like Behavior and Inhibits the Hypothalamus-Pituitary-Adrenal Axis in a Rat Model.

Authors:  Li-Wei Hou; Ji-Liang Fang; Jin-Ling Zhang; Lei Wang; Dong Wu; Jun-Ying Wang; Mo-Zheng Wu; Pei-Jing Rong
Journal:  Dig Dis Sci       Date:  2022-01-22       Impact factor: 3.487

Review 10.  Altered Vagal Signaling and Its Pathophysiological Roles in Functional Dyspepsia.

Authors:  Hui Li; Amanda J Page
Journal:  Front Neurosci       Date:  2022-04-22       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.